These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27788301)

  • 81. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    Melloni C; Cornel JH; Hafley G; Neely ML; Clemmensen P; Zamoryakhin D; Prabhakaran D; White HD; Fox KA; Ohman EM; Armstrong PW; Roe MT
    Eur Heart J Acute Cardiovasc Care; 2016 Oct; 5(6):443-454. PubMed ID: 26228448
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
    Coons JC; Iasella CJ; Chanas T; Wang N; Williams K; Boyd A; Lyons J; Eckardt J; Rihtarchik L; Merkel A; Chambers A; Lemon LS; Smith R; Ensor CR
    Ann Pharmacother; 2017 Aug; 51(8):649-655. PubMed ID: 28438043
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
    Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
    [TBL] [Abstract][Full Text] [Related]  

  • 84. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
    Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
    PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
    Hariri E; Lessard D; Gore J; Rade J; Goldberg R
    Cardiovasc Revasc Med; 2020 Feb; 21(2):182-188. PubMed ID: 31129036
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
    Kim K; Lee TA; Ardati AK; DiDomenico RJ; Touchette DR; Walton SM
    Pharmacotherapy; 2017 Aug; 37(8):877-887. PubMed ID: 28555946
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
    Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
    J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.
    Federspiel JJ; Anstrom KJ; Xian Y; McCoy LA; Effron MB; Faries DE; Zettler M; Mauri L; Yeh RW; Peterson ED; Wang TY;
    JAMA Cardiol; 2016 Sep; 1(6):655-65. PubMed ID: 27438179
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Ferri LA; Morici N; Grosseto D; Tortorella G; Bossi I; Sganzerla P; Cacucci M; Sibilio G; Tondi S; Toso A; Ferrario M; Gandolfo N; Ravera A; Mariani M; Corrada E; Di Ascenzo L; Petronio AS; Cavallini C; Moffa N; De Servi S; Savonitto S
    Am Heart J; 2016 Nov; 181():101-106. PubMed ID: 27823681
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention.
    Davlouros P; Xanthopoulou I; Goudevenos J; Hamilos M; Vavuranakis E; Sitafidis G; Kanakakis I; Deftereos S; Alexopoulos D
    Cardiology; 2017; 138(3):186-194. PubMed ID: 28750372
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Jackson LR; Piccini JP; Cyr DD; Roe MT; Neely ML; Martinez F; Lüscher TF; Lopes RD; Winters KJ; White HD; Armstrong PW; Fox KA; Prabhakaran D; Bhatt DL; Magnus Ohman E; Corbalán R
    Clin Cardiol; 2016 Sep; 39(9):497-506. PubMed ID: 27468086
    [TBL] [Abstract][Full Text] [Related]  

  • 99. ISAR-REACT 5 - What have we learned?
    Kubica J; Jaguszewski M
    Cardiol J; 2019; 26(5):427-428. PubMed ID: 31536136
    [No Abstract]   [Full Text] [Related]  

  • 100. In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome.
    Ohya M; Shimada T; Osakada K; Kuwayama A; Miura K; Murai R; Amano H; Kubo S; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Katoh H; Goto T; Kadota K
    Circ J; 2018 Jun; 82(7):1874-1883. PubMed ID: 29695656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.